Wuxi Jichen Biotechnology Co., Ltd. & Tianjin University of Science and Technology, College of Biological Engineering

Reach Strategic Cooperation

On November 16-17, 2024, the Symposium on the Development of New Quality Productivity in Biotechnology and Fermentation was Successfully Held at the Binhai Campus of Tianjin University of Science and Technology. To better promote industry-university-research cooperation and exchange,Wuxi Jichen Biotechnology Co., Ltd. and the College of Biological Engineering at Tianjin University of Science and Technology Reach Consensus on In-Depth Cooperation, and took this seminar as an opportunity to sign a cooperation agreement during the opening ceremony of the conference.

Shanghai Jichen Biotechnology Co., Ltd. was established in 2017 as a specialized design and manufacturing company in the bioreactor niche, focusing on the research, development, and production of bioreactor laboratory and production equipment, as well as related automation control technologies.

Bioreactors are high-end equipment used in the research and development of biopharmaceuticals and cell culture processes, and they also represent a key technology supporting the large-scale production of biological products. However, as core production equipment for upstream processes in the pharmaceutical industry, the current import substitution rate for bioreactors used in cell culture is less than 30%. At present, almost all commercially-used stainless steel cell reactors in China are imported, with the overall market for bioreactors being monopolized by overseas giants. Meanwhile, with increasing attention to supply chain security, autonomy, timeliness, and cost control, accelerating the localization of upstream "chokepoint" pharmaceutical equipment has become a trend. This presents a significant opportunity for the domestic bioreactor market to experience accelerated import substitution and move toward high-end biopharmaceutical equipment.

Wuxi Jichen Biotechnology Co., Ltd. Large-Scale Stainless Steel Bioreactor

Lingyi Biotech and Zhejiang Jolly Pharmaceutical Co., Ltd. Reach Strategic Cooperation

On November 20, Lingyi Biotech Co., Ltd. ("Lingyi Biotech") and Zhejiang Jolly Pharmaceutical Co., Ltd. ("Jolly Pharmaceutical") solemnly signed the "Strategic Cooperation Framework Agreement" at the headquarters of Jolly Pharmaceutical. Dr. Lin Qing, founder and CEO of Lingyi Biotech, and Mr. Yu Youqiang, Chairman of Jolly Pharmaceutical, attended the signing ceremony as representatives of both parties.Signed this landmark "Strategic Cooperation Framework Agreement"。

According to the "Strategic Cooperation Framework Agreement", both parties willDeep cooperation will be carried out by fully integrating respective advantages in equity cooperation, R&D cooperation, and sales cooperation.Zhejiang Jolly Pharmaceutical Co., Ltd. will fully utilize the capital advantages of being a listed company as well as its strengths in drug research and development, registration application, commercialization, and more, to assist Lingyi Biotech in advancing the R&D of existing drugs, along with future registration applications, commercialization, and other tasks. Lingyi Biotech will leverage its advantages in drug discovery, optimization screening, pharmacology, and efficacy to support Zhejiang Jolly Pharmaceutical Co., Ltd. in drug development, further capturing the domestic and international markets. Both parties will establish corresponding communication and meeting mechanisms to study and resolve major issues during the cooperation, determine relevant policies, and promote the substantive progress of cooperative projects.

Mr. Wang Tao, General Manager of Zhejiang Jolly Pharmaceutical Co., Ltd.:We are very pleased to hold the strategic cooperation signing ceremony between Zhejiang Jolly Pharmaceutical Co., Ltd. and Lingyi Biotech here, which is a significant milestone in the development of both parties. During the exchanges with the Lingyi Biotech team, Jolly Pharmaceutical deeply appreciated the pragmatism, professionalism, and dedication of the Lingyi Biotech team. We hope that through this strategic cooperation, Jolly Pharmaceutical can fully leverage its capital advantages as a listed company and its strengths in drug research and development, registration applications, and commercialization; Lingyi Biotech can also utilize its existing strengths in drug discovery, optimization screening, pharmacology, and efficacy. Both parties will collaborate in various aspects such as equity, R&D, sales, and products, forming a synergy to achieve mutual benefits and win-win results.

Lingyi Biotech Founder and CEO Dr. Lin Qing:We are very grateful to Chairman Yu Youqiang and Zhejiang Jolly Pharmaceutical Co., Ltd. for their recognition and trust in Lingyi Biotech, giving us the opportunity to strategically cooperate with a nationally renowned pharmaceutical listed company like Jolly Pharma. Jolly Pharma is a rare biopharmaceutical company in the traditional Chinese medicine industry that possesses an innovative gene. Based on innovative modern biotechnology and guided by modern traditional Chinese medicine theory, it continuously introduces new products, forming two series of products: Wuling and Bailing. In 2016, Jolly Pharma strategically invested in Carsgen Therapeutics in the CAR-T field, starting its layout in the direction of precision medicine. Carsgen Therapeutics has now successfully gone public, fully demonstrating Jolly's foresight and decision-making ability. Following the investment in cell therapy at Carsgen Therapeutics, Jolly further expanded its layout in the advanced therapy field, fully reflecting its strategic height and forward-looking vision. Lingyi Biotech will further increase the R&D efforts of its pipeline, using excellent clinical data and milestone progress to reward investors.

Zhejiang Jolly Pharmaceutical Co., Ltd.It is a Growth Enterprise Market listed company on the Shenzhen Stock Exchange, stock code: 300181. It is a national high-tech modern biopharmaceutical enterprise that integrates scientific research, production, and sales, mainly engaged in the research, production, and sales of medicinal fungi Wuling and Bailin series products, traditional Chinese medicine decoction pieces, and traditional Chinese medicine formula granules. It has strategically invested in CARSgen Therapeutics Co., Ltd. (referred to as "CARSgen," stock code HK2171) in the field of cell and gene therapy, and plans to further expand its presence in the advanced therapy sector.

Lingyi BiotechFounded in February 2021, Lingyi Biotech is a globally leading company in the development of innovative drugs for monogenic hereditary diseases. The company boasts an internationally top-tier team in gene therapy discovery, research and development, and industrialization, focusing on the R&D and commercialization of First-In-Class gene therapy pipelines. Rooted in original innovation, the company concentrates on disease areas with urgent clinical needs such as metabolism, the central nervous system, and ophthalmology. Starting with key technologies like animal models of genetic diseases, it aims to provide patients with one-time solutions under the highest quality standards.

Youji Medicine and China Radiation Protection Institute Drug Safety Evaluation Center

Reach Strategic Cooperation

On November 21, Tianjin Youji Pharmaceutical Technology Development Co., Ltd. ("Youji Pharma") and the Drug Safety Evaluation Center of China Institute for Radiation Protection ("CIRP Safety Eval Center") signed a strategic cooperation agreement at Youji Pharma. Dr. Si Duanyun, Chairman of Youji Pharma, Dr. Li Chao, General Manager, and Dr. Gu Yuan, Chief Technology Officer, along with Dr. Li Jianguo and Dr. Gao Jie, leaders from CIRP Safety Eval Center, attended the meeting and participated in the signing ceremony. They reached broad consensus on establishing an integrated evaluation system for radiopharmaceuticals.

This strategic agreement signing marks that Youji Pharmaceutical and the Safety Evaluation Center of the China Institute for Radiation Protection (CIRP) will launch comprehensive and in-depth cooperation in the field of non-clinical research for radiopharmaceuticals., by integrating their respective technical and resource advantages,Achieving the Goal of Building a One-Stop Non-Clinical System Evaluation Technology Platform for Nuclear Medicine, and jointly contribute to the vigorous development of China's radiopharmaceutical R&D.

Dr. Li Jianguo, TFM of the Safety Evaluation Center at China Radiation Research Institute, and Dr. Li Chao, TFM of the Safety Evaluation Center at Youji Pharmaceutical, sign agreement and take photo together

Radiation Safety Evaluation Center of China Institute for Radiation ProtectionIt is the earliest professional institution in China to carry out safety evaluations of radiopharmaceuticals, possessing the first non-clinical (GLP) research qualification for new nuclear medicine drugs issued by the NMPA, and has successively completed40More than 10 diagnostic and therapeutic nuclear medicines for non-clinical safety evaluation. Youji Pharmaceutical has established a one-stop non-clinical evaluation system for chemical drugs, natural drugs, and biologics, including pharmacodynamics, pharmacokinetics, and toxicology. This in-depth cooperation with the Safety Evaluation Center of the China Institute for Radiation Protection achievesNuclear Medicine EvaluationThe strong alliance in the field will have the capability to undertake one-stop non-clinical research services for nuclear medicine, further enhancing Youji Pharmaceutical'sCompetitiveness in the Field of Non-Clinical Research for Nuclear Medicine, providing customers with more comprehensive and professional technical support.

Youji PharmaIt is a CRO company under the Asymchem Group (Stock Code: 002821.SZ / 06821.HK) that focuses on pharmacology, toxicology, and pharmacokinetic evaluation for new drugs. It provides services such as early drug-likeness screening, comprehensive preclinical pharmacology and toxicology evaluation, clinical-stage pharmacological research, and bioanalytical testing. Headquartered in the Tianjin Economic-Technological Development Area, it has laboratories located in the FT One Life Science Park in Pudong New Area, Shanghai, with total facilities covering an area of over 13,000 square meters.